Cerebrolysin.
Brain-derived peptide mix. Serious neuroprotection. Neurotrophic peptide mix supporting neuronal repair and plasticity.
Reviewed March 2026
- Category
- Nootropic
- Also filed under
- NeuroprotectionStroke recoveryDementia
What Cerebrolysin is, and what it does.
- Does it work
- Mixed evidence. Some trials positive, others negative. Used clinically in Europe and Asia.
- How much to take
- 5 to 20mg a day is the band on record, given by injection under a clinician. It isn't self-dosed, and an oral peptide product doesn't deliver the same molecules.
- Time to feel it
- Courses run over weeks. Change is picked up on clinician-administered cognitive testing across a course rather than as a same-week sensation.
- The first dose
- Day one is a clinic visit. Some people report soreness at the injection site or brief dizziness. The signalling effects are measured over weeks, not hours.
- With regular use
- Treatment courses run weeks to months. Not acute effects.
- How well tolerated
- Requires medical supervision. Injection site reactions, dizziness possible. Prion concerns theoretical.
- How it feels
- Variable. Some report cognitive improvement over treatment course. Medical supervision required.
- The overlooked benefit
- It isn't one molecule. The spec is a size cut-off, peptides under about ten kilodaltons, so batch consistency rests on the filtration step rather than a single marker.
5 to 20mg a day is where Cerebrolysin works.
Source: Drugs Aging. 2013;30(11):877-889. Cerebrolysin for dementia.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Based on 30 human trials.
- Cognitive performance in older adultsRandomised trial
- Expression of neurotrophic factors, a marker of pathway activityAnimal study
- Shifts in inflammatory signalling markersAnimal study
Questions people ask about Cerebrolysin.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Citicoline supplies cytidine and choline for phosphatidylcholine synthesis, the raw material for building and maintaining neuronal membranes. Cerebrolysin is a peptide preparation studied for its action on neurotrophic signalling, so the two address different halves of the same structural process, the precursor and the signal.
Glutathione appears alongside cerebrolysin in the literature index, generally as a measured redox marker in the same experiments rather than as a co-administered agent. Both sit in the same oxidative-stress readout space. Any pairing rationale here is mechanistic and marker-level, and the co-occurrence is not evidence of a combination effect.
N-acetylcysteine supplies cysteine for glutathione synthesis, which is the endogenous side of the redox markers reported in cerebrolysin experiments. The two act by completely different routes, one a peptide preparation and one a thiol precursor. No combination study exists.
Choline is the upstream substrate for both acetylcholine and membrane phospholipid synthesis. It is the plainest form of the precursor argument used for the choline donors paired with cerebrolysin in the literature. Precursor availability is a mechanism, not a demonstrated combination effect.
DHA is the dominant long-chain polyunsaturated fatty acid in neuronal membranes and is the structural counterpart to a peptide preparation acting on signalling. The two address different layers, membrane composition and trophic signalling. Nothing in the candidate literature tests them together.
Marine omega-3 fatty acids appear in reviews of nutritional support during recovery from mild head injury, the same review space where cerebrolysin is named. Being discussed in one review is co-mention, not a combination result. Additive bleeding risk considerations belong to the omega-3 side, not to cerebrolysin.
Phosphatidylserine is a neuronal membrane phospholipid taken orally for cognitive support, a different class and a different route from an injected peptide concentrate. The pairing rationale is structural support alongside signalling. Untested together.
Coenzyme Q10 carries electrons in the mitochondrial respiratory chain and recycles vitamin E in membranes, so it sits in the bioenergetic and redox space that cerebrolysin experiments report markers from. This is a mechanistic adjacency only.
Acetyl-L-carnitine moves acetyl groups and supports fatty acid transport into mitochondria, and it is used orally in neurological support contexts. It shares no pathway with a peptide hydrolysate. The rationale is bioenergetic support alongside, not with, cerebrolysin.
Nothing specific on file for Cerebrolysin. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Cerebrolysin actually does.
Cerebrolysin is not a single molecule. It is a standardised aqueous mixture of low molecular weight peptides and free amino acids produced by controlled enzymatic proteolysis of porcine brain tissue, with the peptide fraction specified below roughly ten kilodaltons and larger proteins and lipids removed.
It is given parenterally, by injection or infusion, and that route is not incidental. Peptides taken by mouth are substrate for gastric pepsin and pancreatic proteases and for brush-border peptidases, so an oral product cannot be assumed to deliver the same molecules to the circulation as the injected preparation studied in the literature.
Because the starting material is pig brain tissue, the ingredient is of porcine animal origin, which rules it out for vegetarian, vegan, halal and kosher use and makes source-animal control part of its specification.
The mechanistic case put forward for the preparation is neurotrophic-like signalling, and the reported readouts in the retrieved preclinical work are expression of neurotrophic factors and shifts in inflammatory signalling. Those are markers of pathway activity, not measures of function.
Where Cerebrolysin comes from.
Pig brain tissue is broken down with enzymes into short peptides, the fat and big proteins are filtered out, and what is left is standardised into a sterile liquid given by injection. It is an animal tissue extract, not a plant or fermented ingredient, and it is not an oral supplement in the form that has been studied.
Made from an animal material. Species and tissue are the things worth knowing, and both belong on a label.
Brain tissue from pigs sourced through a veterinary-controlled abattoir chain. Source-animal health control and traceability are part of the specification for any bovine or porcine central nervous tissue material.
A standardised protease digest breaks tissue protein down to short peptides and free amino acids under held pH, temperature and time, which is what makes the resulting peptide profile reproducible rather than arbitrary.
Lipid and high molecular weight protein fractions are separated out by filtration steps, and the aqueous peptide fraction is retained.
The retained fraction is specified below approximately ten kilodaltons, with peptide and amino acid content assayed and pyrogen and sterility limits applied.
Filled as a sterile solution for parenteral administration.
Getting Cerebrolysin from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- A retrospective cohort compared combined citicoline and cerebrolysin against comparison care on neurological scores after head injury; a retrospective cohort can show association only, and treatment assignment was not randomised.Cohort study. Schlager et al., 2025 (Frontiers in Neurology). PMID 41409218 ↗
- Cerebrolysin with citicoline was reported to raise brain-derived neurotrophic factor expression in a non-human model; that is a signalling marker in animals, not a functional outcome in people.Animal study. P et al., 2024 (Cureus). PMID 38524067 ↗
- Cerebrolysin loaded into platelet-rich-plasma exosomes shifted TNF alpha and IL-10 signalling and apoptosis markers in a preclinical spinal cord model; the retrieved record does not state the species, and all readouts are markers.Animal study. Akbari-Gharalari et al., 2026 (The Journal of Spinal Cord Medicine). PMID 40470992 ↗
- A comparative review ranked neuroprotective agents on neurological function scales in acute hospital neurology care; cerebrolysin is one of the compared agents rather than the review's subject, and the ranking is of pooled scale scores.Meta-analysis. Wang et al., 2024 (Frontiers in Neuroscience). PMID 39834702 ↗
- A narrative review of nutritional support during recovery from mild head injury names cerebrolysin among the interventions discussed; a mention inside a broader review, with no pooled estimate.Narrative review. Finnegan et al., 2022 (Frontiers in Nutrition). PMID 36313085 ↗
These are the studies our verdict leans on, chosen from the 5 we read for Cerebrolysin. The full linked list is below.
The studies, linked.
12 sources behind our Cerebrolysin verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialCerebrolysin REGistry Study in Stroke A Registry Study to Assess Practices, Safety and Effectiveness of Cerebrolysin in Routine Treatment of Acute Ischemic StrokeClinicalTrials.gov ↗1,823 participants · Terminated
- Clinical trialA Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular DementiaClinicalTrials.gov ↗PHASE4 · 242 participants · Completed
- Clinical trialThe Impact and Outcomes of Combined Cerebrolysin and Amantadine Sulfate Administration on Management of Patients With Traumatic Brain Injury in the ICUClinicalTrials.gov ↗PHASE3 · 150 participants · Completed
- Clinical trialEffects of Cerebrolysin on Motor Recovery in Patients With Subacute StrokeClinicalTrials.gov ↗PHASE4 · 71 participants · Completed
- Clinical trialPhase (2) Clinical Trial Studying the Effect of Cerebrolysin on Physical and Mental Functions of Down SyndromeClinicalTrials.gov ↗PHASE2 · 64 participants · Completed
- Clinical trialCerebrolysin in Patients Diagnosed With SAH - an Observational Cohort Study (PILOT)ClinicalTrials.gov ↗47 participants · Completed
- Clinical trialA Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin in Patients With Traumatic Brain InjuryClinicalTrials.gov ↗PHASE4 · 46 participants · Terminated
- Clinical trialNavigation Brain Stimulation (NBS) for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.ClinicalTrials.gov ↗PHASE3 · 30 participants · Completed
- Clinical trialIMPULSE StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE A Prospective, Multi-center, Randomized, Double-blind Study to Assess Efficacy and Safety of Neuroplastic Intervention by Cerebrolysin and atDCS on Motor Function Recovery in Subacute and Chronic Stroke PatientsClinicalTrials.gov ↗PHASE2 · 4 participants · Terminated
- Clinical trialThe Usefulness of Cerebrolysin in Alleviating the Severity of Delirium in Critically Ill PatientsClinicalTrials.gov ↗NA · 500 participants · Enrolling by invitation
- Clinical trialCERebrolysine Effect on Blood-brain Barrier / Endothelium Integrity During Reperfusion Therapy of acUte Ischemic Stroke (CERBERUS Study)ClinicalTrials.gov ↗PHASE4 · 350 participants · Unknown
- Clinical trialEffect of Nerve Growth Factor (Cerebrolysin) Therapy on Neurodevelopment, Sleep Pattern and Quality of Life in Children With Traumatic Brain Injury and Cerebral PalsyClinicalTrials.gov ↗PHASE2 · 100 participants · Unknown
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Problems people have reported.
Read this carefully. These are 359 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Cerebrolysin is, not how risky it is. A report is not proof Cerebrolysin caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.